Sabitlenmiş Tweet
One thing I think people are massively missing in the GLP-1 / retatrutide debate:
The populations in these studies are usually:
-older
-severely overweight or obese
-metabolically unhealthy
-often sedentary
-low protein intake
-not resistance training
-on multiple cardiometabolic medications
Then people in the biohacker / fitness space who are already 12–20% body fat, resistance training 4–6x/week, eating high protein, optimized hormones, good sleep, etc try to directly apply those outcomes to themselves.
That’s where a lot of the confusion comes from.
People keep making blanket statements like:
“Look how much muscle loss happens on GLP-1s.”
But in my clinical experience, younger healthier metabolically optimized patients often preserve muscle VERY well especially when:
-protein is adequate
-resistance training is present
-weight loss is gradual
-hormones are optimized
-sleep/recovery are good
Taking a 40-year-old lifter from 20% body fat → 15% body fat is NOT the same physiological situation as taking a 72-year-old sedentary diabetic from 38% body fat → 25%.
Those are completely different humans with completely different metabolic environments.
This is why individualized medicine matters.
The real nuance isn’t:
“Tirzepatide vs Retatrutide”
or
“GLP-1s are good/bad”
The real nuance is:
-Who is the patient?
-What is their starting point?
-What are their goals?
-What are they doing with training, protein, hormones, sleep, and lifestyle while using these tools?
English
